Securities Code: 300759
Securities Abbreviation: Kanglonghua
Announcement Number: 2026-046
Kanglonghua (Beijing) Pharmaceutical Technology Co., Ltd.
Announcement on the Completion of the Board of Directors Election and Appointment of Senior Management and Securities Affairs Representatives
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or major omissions.
Kanglonghua (Beijing) Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") shareholders' meeting and the employee representative assembly have respectively elected the fourth board of directors' executive directors, non-executive directors, independent non-executive directors, and employee representative directors. On June 15, 2026, the Company held the first meeting of the fourth Board of Directors, which reviewed and approved proposals for the election of the Chairman of the fourth Board of Directors and members of the Board's special committees, the appointment of senior management, and the appointment of securities affairs representatives. The details are as follows:
I. Composition of the Fourth Board of Directors
Executive Directors: Dr. Boliang Lou (Chairman), Mr. Xiaoqiang Lou, Ms. Bei Zheng
Employee Representative Director: Mr. Chengzong Li (Gilbert Shing Chung Li)
Non-executive Director: Ms. Xuan Wan
Independent Non-executive Directors: Ms. Lihua Li, Professor Jin Feng Zeng (King Fung Tsang), Ms. Rong Shen
The term of office for the fourth Board of Directors is three years, commencing from the date approved by the annual shareholders' meeting in 2025. The number of directors who concurrently serve as senior management personnel of the Company and directors appointed by employee representatives does not exceed one-half of the total number of directors of the Company, and the number of independent non-executive directors is not less than one-third of the total number of directors of the Company. The Company has signed service contracts with the directors of the fourth Board of Directors. Executive directors and employee representative directors do not receive board remuneration; they receive remuneration based on their positions within the Company. Their remuneration for 2026 will consist of a base salary plus performance-based compensation, with the performance-based compensation accounting for no less than 50% of the total base and performance-based compensation. The base salary will be determined with reference to market standards for similar positions, taking into account factors such as position, responsibilities, capabilities, and work location, and will be paid monthly. Performance-based compensation will be determined based on individual performance appraisal results and the Company's operating conditions. Non-executive directors do not receive remuneration from the Company. The annual allowance for independent non-executive directors is RMB 350,000 (pre-tax), which is determined based on their responsibilities and current market conditions, and will be paid monthly, with the Company withholding and remitting personal income tax. The Company will reimburse directors for all necessary and actual expenses incurred in attending board meetings, special committee meetings, and shareholders' meetings.
The resumes of the above-mentioned board members are detailed in the appendix to this announcement and in the "Announcement on the Election of the Board of Directors" disclosed on the Juchao Information Network (www.cninfo.com.cn).
II. Composition of the Fourth Board of Directors' Special Committees
In accordance with the "Company Law of the People's Republic of China," the "Articles of Association," and other relevant laws and regulations, the Company's Board of Directors has established four special committees: the Strategy Committee, the Audit Committee, the Nomination Committee, and the Remuneration and Appraisal Committee. The members of the fourth Board of Directors' special committees are as follows: